Save billions or stick with Humira? Drug brokers steer Americans to the costly choice
Makers of biosimilars must still work within a health care system in which basic economics rarely seems to hold sway.
Source: mmm-online.com
Stay updated with breaking news from Greg Baker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Makers of biosimilars must still work within a health care system in which basic economics rarely seems to hold sway.
Thousands of patients with autoimmune diseases who rely on Humira could get financial relief from new low-cost rivals — if pharmacy benefit managers would get on board.
So why is it so bad to call out racism when we see it, but okay to be racist?
Memorabilia is surfacing online, from framed jerseys to posters and a neon sign.